-
A five years malaria surveillance data analysis of North Shewa zone, Amhara region, Ethiopia: July 2018 to June 2023 Malaria J. (IF 3.0) Pub Date : 2024-06-15 Tebabere Moltot, Girma Bekele, Zenebe Abebe Gebreegziabher, Tesfansh Lemma, Moges Sisay, Mulualem Silesh, Melkam Mulugeta, Legesse Demissie, Tirusew Nigussie Kebede, Birhan Tsegaw Taye
Malaria is a critical public health concern in Ethiopia, with significant socioeconomic consequences. Malaria data trend analysis is essential for understanding transmission patterns and adopting evidence-based malaria control measures. The purpose of this study was to determine the 5 year distribution of malaria in North Shewa zone, Amhara region, Ethiopia, in 2023. A descriptive cross-sectional study
-
Prognostics of multiple malaria episodes and nutritional status in children aged 6 to 59 months from 2013 to 2017 in Dangassa, Koulikoro region, Mali Malaria J. (IF 3.0) Pub Date : 2024-06-13 Soumba Keita, Oumar Thiero, Mahamoudou Toure, Fousseyni Kane, Moussa Keita, Ibrahim Sanogo, Drissa Konate, Daouda Sanogo, Sory Ibrahim Diawara, Hamady Coulibaly, Sidibé M.’Baye Thiam, Nafomon Sogoba, Mahamadou Diakite, Seydou Doumbia
In Africa, the relationship between childhood nutritional status and malaria remains complex and difficult to interpret. Understanding it is important in the improvement of malaria control strategies. This study aimed to assess the influence of nutritional status on the occurrence of multiple malaria episodes in children aged 6 to 59 months between 2013 and 2017 living in the village of Dangassa, Mali
-
Core principles of Malakit intervention for transferability in other contexts Malaria J. (IF 3.0) Pub Date : 2024-06-13 Maylis Douine, Yann Lambert, Muriel Suzanne Galindo, Irene Jimeno Maroto, Teddy Bardon, Lorraine Plessis, Louise Mutricy, Jane Bordallo-Miller, Mathieu Nacher, Antoine Adenis, Hedley Cairo, Hélène Hiwat, Stephen Vreden, Carlotta Carboni, Alice Sanna, Martha Suarez-Mutis
To eliminate malaria, all populations must be included. For those who are not reached by the health care system, specific interventions must be tailor-made. An innovative Malakit strategy, based on the distribution of self-diagnosis and self-treatment kits, has been evaluated in the Suriname-French Guiana- Amapá (Brazil) region. The results showed effectiveness and good acceptability. The Malakit intervention
-
Therapeutic efficacy and safety of artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria treatment in Metehara, Central-east Ethiopia Malaria J. (IF 3.0) Pub Date : 2024-06-12 Mahelet Tesfaye, Ashenafi Assefa, Henok Hailgiorgis, Bokretsion Gidey, Hussein Mohammed, Getachew Tollera, Geremew Tasew, Gudissa Assefa, Worku Bekele, Hassen Mamo
Malaria remains a major global health problem although there was a remarkable achievement between 2000 and 2015. Malaria drug resistance, along with several other factors, presents a significant challenge to malaria control and elimination efforts. Numerous countries in sub-Saharan Africa have documented the presence of confirmed or potential markers of partial resistance against artemisinin, the drug
-
Chloroquine has shown high therapeutic efficacy against uncomplicated Plasmodium vivax malaria in southern Ethiopia: seven decades after its introduction Malaria J. (IF 3.0) Pub Date : 2024-06-10 Anteneh Kassahun Mare, Hussein Mohammed, Heven Sime, Henok Hailgiorgis, Kale Gubae, Bekuretsion Gidey, Mebrahtom Haile, Gudissa Assefa, Worku Bekele, Sarah Auburn, Rick Price, Jonathan B. Parr, Jonathan J. Juliano, Geremew Tasew, Solomon Mequanente Abay, Ashenafi Assefa
Plasmodium vivax malaria is a leading cause of morbidity in Ethiopia. The first-line treatment for P. vivax is chloroquine (CQ) and primaquine (PQ), but there have been local reports of CQ resistance. A clinical study was conducted to determine the efficacy of CQ for the treatment of P. vivax malaria in southern Ethiopia. In 2021, patients with P. vivax mono-infection and uncomplicated malaria were
-
Community readiness and acceptance for the implementation of a novel malaria vaccine among at-risk children in sub-saharan Africa: a systematic review protocol Malaria J. (IF 3.0) Pub Date : 2024-06-10 Eustes Kigongo, Amir Kabunga, Marc Sam Opollo, Raymond Tumwesigye, Marvin Musinguzi, Anne Ruth Akello, Jannat Nabaziwa, Temesgen Geta Hardido, Sean Steven Puleh
The World Health Organization novel malaria vaccine for at-risk children has the potential to greatly reduce the current malaria burden in sub-Saharan Africa. However, most studies have reported contradictory findings regarding community willingness for the vaccine, which could easily undermine the expected benefits of the vaccine. This study aims to ascertain the current state of community readiness
-
Drivers of autochthonous malaria cases over time: could the Central European present the African future? Malaria J. (IF 3.0) Pub Date : 2024-06-10 Zoltán Kenyeres
Results of spatial and temporal comparison of malaria hotspots and coldspots could improve the health measures of malaria control and eradication strategies. The study aimed to reveal the spatially and temporally independent correlations between the potentially most effective background variables and the number of autochthonous malaria cases. Relationships between malaria cases and background variables
-
LLIN Evaluation in Uganda Project (LLINEUP): modelling the impact of COVID-19-related disruptions on delivery of long-lasting insecticidal nets on malaria indicators in Uganda Malaria J. (IF 3.0) Pub Date : 2024-06-06 Jaffer Okiring, Samuel Gonahasa, Catherine Maiteki-Sebuguzi, Agaba Katureebe, Irene Bagala, Peter Mutungi, Simon P. Kigozi, Jane F. Namuganga, Joaniter I. Nankabirwa, Moses R. Kamya, Martin J. Donnelly, Thomas S. Churcher, Sarah G. Staedke, Ellie Sherrard-Smith
Disruptions in malaria control due to COVID-19 mitigation measures were predicted to increase malaria morbidity and mortality in Africa substantially. In Uganda, long-lasting insecticidal nets (LLINs) are distributed nationwide every 3–4 years, but the 2020–2021 campaign was altered because of COVID-19 restrictions so that the timing of delivery of new nets was different from the original plans made
-
Screening blood donors for malaria, can we increase the number of eligible donors? An observational retrospective study Malaria J. (IF 3.0) Pub Date : 2024-06-06 María Dolores Corbacho-Loarte, Oihane Martín, Sandra Chamorro-Tojeiro, Clara Crespillo-Andújar, Francesca F. Norman, José A. Pérez-Molina, Marta González Sanz, Marta Rosas Cancio-Suárez, Gabriel Ruiz-Calvo, Alberto Richart López, José Miguel Rubio, Rogelio López-Vélez, Begoña Monge-Maillo
In non-endemic countries, malaria can be transmitted through blood donations from imported cases. To ensure standards of quality and safety of human blood, the European Union and Spanish national law, requires a deferral period, or a screening by immunological or genomic test among those donors with potential risk of malaria. Scientific societies, European Committee on Blood Transfusion, and Spanish
-
Plasmodium falciparum neonatal malaria with atypical presentation: a case series from southwestern Ethiopia Malaria J. (IF 3.0) Pub Date : 2024-06-05 Zerubabel Girma Tesso, Tariku Yigremachew Gossaye, Dereje Sileshi Bekana, Molla Asnake Kebede, Fikretsion Degemu Besir, Nikodimos Eshetu Dabe
Neonatal malaria is defined as the detection of asexual stages of Plasmodium species in the cord blood within the first 28 days of life. It can be congenital or acquired through mosquito bites or blood transfusions. Neonates are generally considered to be relatively protected due to the multiple innate and acquired physiological protective effects present in neonates. However, in areas where malaria
-
Severe malaria intervention status in Nigeria: workshop meeting report Malaria J. (IF 3.0) Pub Date : 2024-06-05 Emmanuel Shekarau, Miriam Uzoanya, Nnenna Ogbulafor
Nigeria accounts for 39% of global malaria deaths in children under 5 years of age and the effective management of severe malaria is a health priority. The Annual Nigeria Severe Malaria Stakeholders Workshop, held on the 5–6th of July 2023 in Abuja, Nigeria brought together representatives from 36 States, the Federal Capital Territory, and other key stakeholders to address the management of severe
-
Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination Malaria J. (IF 3.0) Pub Date : 2024-06-05 Julie Nguyen Ngoc Pouplin, Thoopmanee Kaendiao, Bilal Ahmad Rahimi, Mayur Soni, Hensi Basopia, Darshana Shah, Jitendra Patil, Vyom Dholakia, Yash Suthar, Joel Tarning, Mavuto Mukaka, Walter R. Taylor
With only one 15 mg primaquine tablet registered by a stringent regulatory authority and marketed, more quality-assured primaquine is needed to meet the demands of malaria elimination. A classic, two sequence, crossover study, with a 10-day wash out period, of 15 mg of IPCA-produced test primaquine tablets and 15 mg of Sanofi reference primaquine tablets was conducted. Healthy volunteers, aged 18–45 years
-
Insufficient duration of insecticidal efficacy of Yahe® insecticide-treated nets in Papua New Guinea Malaria J. (IF 3.0) Pub Date : 2024-06-05 Nakei Bubun, Evodia Anetul, Melanie Koinari, Petrina H. Johnson, Leo S. Makita, Timothy W. Freeman, Leanne J. Robinson, Moses Laman, Stephan Karl
Insecticide-treated nets (ITNs) are the backbone of anti-malarial vector control in Papua New Guinea (PNG). Over recent years the quality and performance of ITNs delivered to PNG decreased, which has likely contributed to the stagnation in the malaria control effort in the country. The present study reports results from the first 24 months of a durability study with the ITN product Yahe LN® in PNG
-
Defining the next generation of severe malaria treatment: a target product profile Malaria J. (IF 3.0) Pub Date : 2024-06-05 Jane Achan, Aïssata Barry, Didier Leroy, George Kamara, Stephan Duparc, Wiweka Kaszubska, Preetam Gandhi, Bénédicte Buffet, Patrick Tshilab, Bernhards Ogutu, Terrie Taylor, Sanjeev Krishna, Naomi Richardson, Hanu Ramachandruni, Hans Rietveld
Severe malaria is a life-threatening infection, particularly affecting children under the age of 5 years in Africa. Current treatment with parenteral artemisinin derivatives is highly efficacious. However, artemisinin partial resistance is widespread in Southeast Asia, resulting in delayed parasite clearance after therapy, and has emerged independently in South America, Oceania, and Africa. Hence,
-
Physical and insecticidal durability of Interceptor®, Interceptor® G2, and PermaNet® 3.0 insecticide-treated nets in Burkina Faso: results of durability monitoring in three sites from 2019 to 2022 Malaria J. (IF 3.0) Pub Date : 2024-06-04 Jacky Raharinjatovo, Roch Kounbobr Dabiré, Keith Esch, Dieudonné Diloma Soma, Aristide Hien, Tiecoura Camara, Mame Birame Diouf, Allison Belemvire, Lilia Gerberg, Taiwo Samson Awolola, Adama Koné, Djenam Jacob, Sophie Vandecandelaere, Marie Baes, Stephen Poyer
National Malaria Programmes (NMPs) monitor the durability of insecticide-treated nets (ITNs) to inform procurement and replacement decisions. This is crucial for new dual active ingredients (AI) ITNs, for which less data is available. Pyrethroid-only ITN (Interceptor®) and dual AI (Interceptor® G2, and PermaNet® 3.0) ITNs were assessed across three health districts over 36 months in southern Burkina
-
75 years’ journey of malaria publications in English: what and where? Malaria J. (IF 3.0) Pub Date : 2024-06-02 Nimita Deora, Sonalika Kar, Veena Pande, Abhinav Sinha
Malaria has inflicted serious morbidity and mortality across the globe. The major brunt of the disease has been on African, South-East Asian and South American countries. Proportionally, malaria has attracted global research priorities and this is evident from the number of publications related to malaria from across the globe, irrespective of its endemicity. However, formal and exhaustive analyses
-
Examining the paradox: increased malaria risk in children under 5 in female-headed households in Nigeria Malaria J. (IF 3.0) Pub Date : 2024-05-31 Si-Yu Xing, Hai-Ting Zhang, Lin-Min Wang, Hong-Zheng Lu, Zhe-Yu Peng, Miao Liu, Chun-Xiao Li, Sheng-Qun Deng
Nigeria is facing a severe malaria crisis, accounting for a significant proportion of global cases and deaths of malaria. This study aimed to investigate the differences between female-headed households (FHHs) and male-headed households (MHHs) and their impact on malaria risk among children under five (U5) in Nigeria. Data from the 2021 Nigeria Malaria Indicator Survey (NMIS) were used for this cross-sectional
-
Health workers’ adherence to malaria case management protocols in Northern Sudan: a qualitative study Malaria J. (IF 3.0) Pub Date : 2024-05-30 Sahar Khalid Mohamed, Duha Khalid Mohamed, Khansaa Ahmed, Fadwa Saad, Dejan Zurovac
Nonadherence to national standards for malaria diagnosis and treatment has been reported in Sudan. In this study, qualitative research examined the clinical domains of nonadherence, factors influencing nonadherent practices and health workers’ views on how to improve adherence. In September 2023, five Focus Group Discussions (FGDs) were undertaken with 104 health workers from 42 health facilities in
-
Residual bioefficacy of attractive targeted sugar bait stations targeting malaria vectors during seasonal deployment in Western Province of Zambia Malaria J. (IF 3.0) Pub Date : 2024-05-29 Gift Mwaanga, Jacob Ford, Joshua Yukich, Benjamin Chanda, Ruth A. Ashton, Javan Chanda, Buster Munsanje, Emliny Muntanga, Malon Mulota, Christine Simuyandi, Boyd Mulala, Limonty Simubali, Kochelani Saili, Edgar Simulundu, John Miller, Busiku Hamainza, Erica Orange, Joseph Wagman, Monicah M. Mburu, Angela F. Harris, Julian Entwistle, Megan Littrell
The primary vector control interventions in Zambia are long-lasting insecticidal nets and indoor residual spraying. Challenges with these interventions include insecticide resistance and the outdoor biting and resting behaviours of many Anopheles mosquitoes. Therefore, new vector control tools targeting additional mosquito behaviours are needed to interrupt transmission. Attractive targeted sugar bait
-
Combined use of long-lasting insecticidal nets and Bacillus thuringiensis israelensis larviciding, a promising integrated approach against malaria transmission in northern Côte d'Ivoire Malaria J. (IF 3.0) Pub Date : 2024-05-29 Jean-Philippe B. Tia, Emile S. F. Tchicaya, Julien Z. B. Zahouli, Allassane F. Ouattara, Laura Vavassori, Jean-Baptiste Assamoi, Graham Small, Benjamin G. Koudou
The recent reduction in malaria burden in Côte d’Ivoire is largely attributable to the use of long-lasting insecticidal nets (LLINs). However, this progress is threatened by insecticide resistance and behavioral changes in Anopheles gambiae sensu lato (s.l.) populations and residual malaria transmission, and complementary tools are required. Thus, this study aimed to assess the efficacy of the combined
-
Ownership and use of insecticide-treated nets in Myanmar: insights from a nationally representative demographic and health survey Malaria J. (IF 3.0) Pub Date : 2024-05-29 Kyawt Mon Win, Kyaw Lwin Show, Jetsumon Sattabongkot, Pyae Linn Aung
Malaria poses a substantial public health threat in Myanmar, indicating the need for rigorous efforts to achieve elimination of the disease nationwide by 2030. The use of insecticide-treated nets (ITNs) forms part of a pivotal strategy for preventing transmission. This study explored the ownership and use of ITNs in Myanmar and identified factors associated with non-use of ITNs. Household datasets
-
Forest cover percentage drives the peak biting time of Nyssorhynchus darlingi (Diptera: Culicidae) in the Brazilian Amazon Malaria J. (IF 3.0) Pub Date : 2024-05-28 Leonardo Suveges Moreira Chaves, Eduardo Sterlino Bergo, Sara A. Bickersmith, Gabriel Z. Laporta, Jan E. Conn, Maria Anice Mureb Sallum
Deforestation is an important driver of malaria dynamics, with a relevant impact on mosquito ecology, including larval habitat availability, blood-feeding behaviour, and peak biting time. The latter is one of several entomological metrics to evaluate vectorial capacity and effectiveness of disease control. This study aimed to test the effect of forest cover percentage on the peak biting time of Plasmodium-uninfected
-
Insecticide susceptibility status of Anopheles albimanus populations in historical malaria foci in Quintana Roo, Mexico Malaria J. (IF 3.0) Pub Date : 2024-05-25 Denis Escobar, Gabriela González-Olvera, Ángel S. Gómez-Rivera, Juan Navarrete-Carballo, Pedro Mis-Ávila, Raquel Baack-Valle, Guillermo Escalante, Gerardo Reyes-Cabrera, Fabian Correa-Morales, Azael Che-Mendoza, Gonzalo Vazquez-Prokopec, Audrey Lenhart, Pablo Manrique-Saide
Mexico has experienced a significant reduction in malaria cases over the past two decades. Certification of localities as malaria-free areas (MFAs) has been proposed as a steppingstone before elimination is achieved throughout the country. The Mexican state of Quintana Roo is a candidate for MFA certification. Monitoring the status of insecticide susceptibility of major vectors is crucial for MFA certification
-
Identifying suitable methods for evaluating the sterilizing effects of pyriproxyfen on adult malaria vectors: a comparison of the oviposition and ovary dissection methods Malaria J. (IF 3.0) Pub Date : 2024-05-24 Alesha Myers, Josias Fagbohoun, Georgine Houetohossou, Boris Ndombidje, Renaud Govoetchan, Damien Todjinou, Corine Ngufor
Nets containing pyriproxyfen, an insect growth regulator that sterilizes adult mosquitoes, have become available for malaria control. Suitable methods for investigating vector susceptibility to pyriproxyfen and evaluating its efficacy on nets need to be identified. The sterilizing effects of pyriproxyfen on adult malaria vectors can be assessed by measuring oviposition or by dissecting mosquito ovaries
-
Evaluation of naturally acquired immune responses against novel pre-erythrocytic Plasmodium vivax proteins in a low endemic malaria population located in the Peruvian Amazon Basin Malaria J. (IF 3.0) Pub Date : 2024-05-23 Julio A. Ventocilla, L. Lorena Tapia, Reynaldo Ponce, Adriano Franco, Mindy Leelawong, Joao C. Aguiar, G. Christian Baldeviano, Brandon K. Wilder
Plasmodium vivax represents the most geographically widespread human malaria parasite affecting civilian and military populations in endemic areas. Targeting the pre-erythrocytic (PE) stage of the parasite life cycle is especially appealing for developing P. vivax vaccines as it would prevent disease and transmission. Here, naturally acquired immunity to a panel of P. vivax PE antigens was explored
-
Towards malaria elimination: a reflection about digital notification modules to improve malaria cases notification speed and follow-up in the Brazilian Amazon region Malaria J. (IF 3.0) Pub Date : 2024-05-23 Klauss Kleydmann Sabino Garcia, Sheila Rodrigues Rodovalho, André M. Siqueira
Health information systems (HIS) are a pivotal element in epidemiological surveillance. In Brazil, malaria persists as a public health challenge, with 99% of its occurrences concentrated in the Amazon region, where cases are reported through the HIS Sivep-Malaria. Recent technological advancements indicate that case notifications can be expedited through more efficient systems with broader coverage
-
The behaviour of adult Anopheles gambiae, sub-Saharan Africa’s principal malaria vector, and its relevance to malaria control: a review Malaria J. (IF 3.0) Pub Date : 2024-05-23 Willem Takken, Derek Charlwood, Steve W. Lindsay
Mosquitoes of the Anopheles gambiae complex are one of the major vectors of malaria in sub-Saharan Africa. Their ability to transmit this disease of major public health importance is dependent on their abundance, biting behaviour, susceptibility and their ability to survive long enough to transmit malaria parasites. A deeper understanding of this behaviour can be exploited for improving vector surveillance
-
Can neonicotinoid and pyrrole insecticides manage malaria vector resistance in high pyrethroid resistance areas in Côte d'Ivoire? Malaria J. (IF 3.0) Pub Date : 2024-05-22 Armand K. Ekra, Constant A. V. Edi, Guy Constant N. Gbalegba, Julien Z. B. Zahouli, Mathias Danho, Benjamin G. Koudou
Anopheles mosquito resistance to insecticide remains a serious threat to malaria vector control affecting several sub-Sahara African countries, including Côte d’Ivoire, where high pyrethroid, carbamate and organophosphate resistance have been reported. Since 2017, new insecticides, namely neonicotinoids (e.g.; clothianidin) and pyrroles (e.g.; chlorfenapyr) have been pre-qualified by the World Health
-
Considerations for first field trials of low-threshold gene drive for malaria vector control Malaria J. (IF 3.0) Pub Date : 2024-05-22 John B. Connolly, Austin Burt, George Christophides, Abdoulaye Diabate, Tibebu Habtewold, Penelope A. Hancock, Anthony A. James, Jonathan K. Kayondo, Dickson Wilson Lwetoijera, Alphaxard Manjurano, Andrew R. McKemey, Michael R. Santos, Nikolai Windbichler, Filippo Randazzo
Sustainable reductions in African malaria transmission require innovative tools for mosquito control. One proposal involves the use of low-threshold gene drive in Anopheles vector species, where a ‘causal pathway’ would be initiated by (i) the release of a gene drive system in target mosquito vector species, leading to (ii) its transmission to subsequent generations, (iii) its increase in frequency
-
Population pharmacokinetics of primaquine and its metabolites in African males Malaria J. (IF 3.0) Pub Date : 2024-05-21 Palang Chotsiri, Almahamoudou Mahamar, Halimatou Diawara, Pius S. Fasinu, Kalifa Diarra, Koualy Sanogo, Teun Bousema, Larry A. Walker, Joelle M. Brown, Alassane Dicko, Roly Gosling, Ingrid Chen, Joel Tarning
Primaquine (PQ) is the prototype 8-aminoquinoline drug, a class which targets gametocytes and hypnozoites. The World Health Organization (WHO) recommends adding a single low dose of primaquine to the standard artemisinin-based combination therapy (ACT) in order to block malaria transmission in regions with low malaria transmission. However, the haemolytic toxicity is a major adverse outcome of primaquine
-
Assessment of environmental and spatial factors influencing the establishment of Anopheles gambiae larval habitats in the malaria endemic province of Woleu-Ntem, northern Gabon Malaria J. (IF 3.0) Pub Date : 2024-05-21 Neil-Michel Longo-Pendy, Silas Lendzele Sevidzem, Boris Kevin Makanga, Saturnin Ndotit-Manguiengha, Stravensky Térence Boussougou-Sambe, Piazzy Obame Ondo Kutomy, Judicaël Obame-Nkoghe, Lynda-Chancelya Nkoghe-Nkoghe, Barclaye Ngossanga, Felicien Kassa Mvoubou, Christophe Roland Zinga Koumba, Ayôla Akim Adegnika, Abdul-Safiou Razack, Jacques François Mavoungou, Rodrigue Mintsa-Nguema
This study aimed to assess the spatial distribution of Anopheles mosquito larval habitats and the environmental factors associated with them, as a prerequisite for the implementation of larviciding. The study was conducted in December 2021, during the transition period between the end of the short rainy season (September–November) and the short dry season (December-February). Physical, biological,
-
Field testing of user-friendly perennial malaria chemoprevention packaging in Benin, Côte d’Ivoire and Mozambique Malaria J. (IF 3.0) Pub Date : 2024-05-21 Sylvain Landry Birane Faye, Maud Majeres Lugand, André Touré Offianan, Aurélie Dossou-Yovo, Dieudonné Kouakou M’Bra Kouadio, Felix Pinto
Perennial malaria chemoprevention (PMC) aims to protect children at risk from severe malaria by the administration of anti-malarial drugs to children of defined ages throughout the year. Sulfadoxine-pyrimethamine (SP) has been widely used for chemoprevention in Africa and a child-friendly dispersible tablet formulation has recently become available. This qualitative non-interventional observational
-
Exploring existing malaria services and the feasibility of implementing community engagement approaches amongst conflict-affected communities in Cameroon: a qualitative study Malaria J. (IF 3.0) Pub Date : 2024-05-20 Margaret Ebob Besem E.O, Elisabeth G. Chestnutt, Laura Donovan, Ann-Sophie Stratil, Helen Counihan, Claude Ngwayu Nkfusai, Helen Hawkings, Blanka Homolova, Kolawole Maxwell, Kevin Baker, Yakouba Zoungrana, Elvis Asangbeng Tanue, Glennise Ayuk, Noukeme Bibiche Modjenpa, Alain Metuge, Isabelle Nganmou, Dorothy Achu, Samuel Wanji, Elizabeth Berryman, Lundi-Anne Omam
Cameroon is one of the countries with the highest burden of malaria. Since 2018, there has been an ongoing conflict in the country, which has reduced access to healthcare for populations in affected regions, and little is known about the impact on access to malaria services. The objective of this study was to understand the current situation regarding access to malaria services in Cameroon to inform
-
IgG and IgM responses to the Plasmodium falciparum asexual stage antigens reflect respectively protection against malaria during pregnancy and infanthood Malaria J. (IF 3.0) Pub Date : 2024-05-19 Mahugnon L. Erasme Gbaguidi, Rafiou Adamou, Sofie Edslev, Anita Hansen, Nadia D. Domingo, Celia Dechavanne, Achille Massougbodji, André Garcia, Michael Theisen, Jacqueline Milet, Eduardo A. Donadi, David Courtin
Plasmodium falciparum malaria is a public health issue mostly seen in tropical countries. Until now, there is no effective malaria vaccine against antigens specific to the blood-stage of P. falciparum infection. Because the pathogenesis of malarial disease results from blood-stage infection, it is essential to identify the most promising blood-stage vaccine candidate antigens under natural exposure
-
Characteristics of the Western Province, Zambia, trial site for evaluation of attractive targeted sugar baits for malaria vector control Malaria J. (IF 3.0) Pub Date : 2024-05-18 Annie Arnzen, Joseph Wagman, Chama Chishya, Erica Orange, Thomas P. Eisele, Joshua Yukich, Ruth A. Ashton, Javan Chanda, Jimmy Sakala, Benjamin Chanda, Rayford Muyabe, Tresford Kaniki, Mwansa Mwenya, Gift Mwaanga, Will T. Eaton, Brooke Mancuso, Alice Mungo, Monicah M. Mburu, Nchimunya Bubala, Ackim Hagwamuna, Edgar Simulundu, Kochelani Saili, John M. Miller, Kafula Silumbe, Busiku Hamainza, Willy Ngulube
The attractive targeted sugar bait (ATSB) is a novel malaria vector control tool designed to attract and kill mosquitoes using a sugar-based bait, laced with oral toxicant. Western Province, Zambia, was one of three countries selected for a series of phase III cluster randomized controlled trials of the Westham ATSB Sarabi version 1.2. The trial sites in Kenya, Mali, and Zambia were selected to represent
-
Ten-year trend analysis of malaria prevalence in Gindabarat district, West Shawa Zone, Oromia Regional State, Western Ethiopia Malaria J. (IF 3.0) Pub Date : 2024-05-16 Kinfu Boresa, Tariku Belay, Abdissa Biruksew, Eshetu Alemayehu, Endalew Zemene
Malaria is a major public health concern in Ethiopia, where more than half of the population lives in malaria risk areas. While several studies have been conducted in different eco-epidemiological settings in Ethiopia, there is a notable scarcity of data on the prevalence of malaria in the Gindabarat district. Therefore, this study aimed to analyse 10-year trend of malaria prevalence in Gindabarat
-
A screen for Plasmodium falciparum sporozoite surface protein binding to human hepatocyte surface receptors identifies novel host–pathogen interactions Malaria J. (IF 3.0) Pub Date : 2024-05-16 Rameswara R. Segireddy, Hugo Belda, Annie S. P. Yang, Kirsten Dundas, Julia Knoeckel, Francis Galaway, Laura Wood, Doris Quinkert, Ellen Knuepfer, Moritz Treeck, Gavin J. Wright, Alexander D. Douglas
Sporozoite invasion of hepatocytes is an essential step in the Plasmodium life-cycle and has similarities, at the cellular level, to merozoite invasion of erythrocytes. In the case of the Plasmodium blood-stage, efforts to identify host–pathogen protein–protein interactions have yielded important insights including vaccine candidates. In the case of sporozoite-hepatocyte invasion, the host–pathogen
-
Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda Malaria J. (IF 3.0) Pub Date : 2024-05-16 Cecile Schreidah, David Giesbrecht, Pierre Gashema, Neeva Wernsman Young, Tharcisse Munyaneza, Claude Mambo Muvunyi, Kyaw Thwai, Jean-Baptiste Mazarati, Jeffrey A. Bailey, Jonathan J. Juliano, Corine Karema
Emerging artemisinin partial resistance and diagnostic resistance are a threat to malaria control in Africa. Plasmodium falciparum kelch13 (k13) propeller-domain mutations that confer artemisinin partial resistance have emerged in Africa. k13-561H was initially described at a frequency of 7.4% from Masaka in 2014–2015, but not present in nearby Rukara. By 2018, 19.6% of isolates in Masaka and 22% of
-
Evidence of Plasmodium vivax circulation in western and eastern regions of Senegal: implications for malaria control Malaria J. (IF 3.0) Pub Date : 2024-05-16 Aida S. Badiane, Bassirou Ngom, Tolla Ndiaye, Deirdre Cunningham, James Campbell, Amy Gaye, Aita Sène, Mouhamad Sy, Daouda Ndiaye, Davis Nwakanma, Jean Langhorne
Malaria elimination in Senegal requires accurate diagnosis of all Plasmodium species. Plasmodium falciparum is the most prevalent species in Senegal, although Plasmodium malariae, Plasmodium ovale, and recently Plasmodium vivax have also been reported. Nonetheless, most malaria control tools, such as Histidine Rich Protein 2 rapid diagnosis test (PfHRP2-RDT,) can only diagnose P. falciparum. Thus,
-
Efficacy of Pirikool® 300 CS used for indoor residual spraying on three different substrates in semi-field experimental conditions Malaria J. (IF 3.0) Pub Date : 2024-05-15 Behi Kouadio Fodjo, Emile Tchicaya, Laurence Aya Yao, Constant Edi, Alassane Foungoye Ouattara, Loukou Bernard Kouassi, Firmain N’dri Yokoly, Koudou Guibéhi Benjamin
Vector control using insecticides is a key prevention strategy against malaria. Unfortunately, insecticide resistance in mosquitoes threatens all progress in malaria control. In the perspective of managing this resistance, new insecticide formulations are being tested to improve the effectiveness of vector control tools. The efficacy and residual activity of Pirikool® 300 CS was evaluated in comparison
-
Cost-effectiveness of village health worker-led integrated community case management (iCCM) versus health facility based management for childhood illnesses in rural southwestern Uganda Malaria J. (IF 3.0) Pub Date : 2024-05-15 Edgar Mulogo, Moses Ntaro, Andrew Wesuta, Jane Namusisi, Peter Kawungezi, Vincent Batwala, Michael Matte
In Uganda, village health workers (VHWs) manage childhood illness under the integrated community case management (iCCM) strategy. Care is provided for malaria, pneumonia, and diarrhoea in a community setting. Currently, there is limited evidence on the cost-effectiveness of iCCM in comparison to health facility-based management for childhood illnesses. This study examined the cost-effectiveness of
-
Mixed-method evaluation study of a targeted mass drug administration of long-acting anti-malarials among children aged 3 months to 15 years in the Bossangoa sub-prefecture, Ouham, Central African Republic, during the COVID-19 pandemic Malaria J. (IF 3.0) Pub Date : 2024-05-15 Eve Robinson, Adelaide Ouabo, Letitia Rose, Felipe van Braak, Jorieke Vyncke, Roberto Wright, Nell Gray, Narcisse Simon Sakama, Emmanuel Joao Aboukar, Methode Mberyo Fierte, Daniel Woinzoukou, Linn Ewers, Christian Serpande, Susanne Stein, Elburg Van Boetzelaer, Odilon Auguste Kpahina, Sosthene Constant Sabe, Bhargavi Rao, Anna Kuehne
In 2020, during the COVID-19 pandemic, Médecins Sans Frontières (MSF) initiated three cycles of dihydroartemisin-piperaquine (DHA-PQ) mass drug administration (MDA) for children aged three months to 15 years within Bossangoa sub-prefecture, Central African Republic. Coverage, clinical impact, and community members perspectives were evaluated to inform the use of MDAs in humanitarian emergencies. A
-
Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria Malaria J. (IF 3.0) Pub Date : 2024-05-13 Raman Sharma, Hema Sharma, Siôn Jones, Isabelle Borghini-Fuhrer, Gonzalo J. Domingo, Rachel A. Gibson, Katie Rolfe, Lionel Tan, Ioana Gabriela Fiţa, Chao Chen, Panayota Bird, Anup Pingle, Stephan Duparc
A single 300 mg dose of tafenoquine (an 8-aminoquinoline), in combination with a standard 3-day course of chloroquine, is approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥ 16 years. Despite this, questions have arisen on the optimal dose of tafenoquine. Before the availability of tafenoquine, a 3-day course of chloroquine in combination
-
Therapeutic efficacy and tolerability of artemether–lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020 Malaria J. (IF 3.0) Pub Date : 2024-05-13 Ibrahim M. Laminou, Ibrahima Issa, Eric Adehossi, Kabirou Maman, Hadiza Jackou, Eric Coulibaly, Zilahatou B. Tohon, Jehan Ahmed, Elisha Sanoussi, Daniel Koko
Monitoring therapeutic efficacy is important to ensure the efficacy of artemisinin-based combination therapy (ACT) for malaria. The current first-line treatment for uncomplicated malaria recommended by the National Malaria Control Program in Niger is artemether–lumefantrine (AL). In 2020, an in vivo study was carried out to evaluate clinical and parasitological responses to AL as well as the molecular
-
Prevalence of malaria and associated risk factors among household members in South Ethiopia: a multi-site cross-sectional study Malaria J. (IF 3.0) Pub Date : 2024-05-12 Girma Yutura, Fekadu Massebo, Nigatu Eligo, Abena Kochora, Teklu Wegayehu
Despite continuous prevention and control strategies in place, malaria remains a major public health problem in sub-Saharan Africa including Ethiopia. Moreover, prevalence of malaria differs in different geographical settings and epidemiological data were inadequate to assure disease status in the study area. This study was aimed to determine the prevalence of malaria and associated risk factors in
-
Hesitancy towards R21/Matrix-M malaria vaccine among Ghanaian parents and attitudes towards immunizing non-eligible children: a cross-sectional survey Malaria J. (IF 3.0) Pub Date : 2024-05-12 Mohamed Fakhry Hussein, Frank Kyei-Arthur, Marina Saleeb, Sylvester Kyei-Gyamfi, Theophilus Abutima, Ignatius Great Sakada, Ramy Mohamed Ghazy
The newly developed malaria vaccine called “R21/Matrix-M malaria vaccine” showed a high safety and efficacy level, and Ghana is the first country to approve this new vaccine. The present study aimed to evaluate the rate of vaccine hesitancy (VH) towards the newly developed malaria vaccine among parents who currently have children who are not eligible for the vaccine but may be eligible in the near
-
Phytochemical evaluation of Ziziphus mucronata and Xysmalobium undulutum towards the discovery and development of anti-malarial drugs Malaria J. (IF 3.0) Pub Date : 2024-05-11 Muzi N. Buthelezi, Vhahangwele G. Tshililo, Abidemi P. Kappo, Mthokozisi B. C. Simelane
The development of resistance by Plasmodium falciparum is a burdening hazard that continues to undermine the strides made to alleviate malaria. As such, there is an increasing need to find new alternative strategies. This study evaluated and validated 2 medicinal plants used in traditional medicine to treat malaria. Inspired by their ethnobotanical reputation of being effective against malaria, Ziziphus
-
Kinetics of glucose-6-phosphate dehydrogenase (G6PD) activity during Plasmodium vivax infection: implications for early radical malaria treatment Malaria J. (IF 3.0) Pub Date : 2024-05-09 Laureen Dahuron, Juste Goungounga, Moustapha Drame, Maylis Douine, Mathieu Nacher, Théo Blaise, Emilie Mosnier, Lise Musset, Marie Fouillet, Félix Djossou, Loïc Epelboin
Plasmodium vivax relapses due to dormant liver hypnozoites can be prevented with primaquine. However, the dose must be adjusted in individuals with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. In French Guiana, assessment of G6PD activity is typically delayed until day (D)14 to avoid the risk if misclassification. This study assessed the kinetics of G6PD activity throughout P. vivax infection
-
Genetic polymorphism and evidence of signatures of selection in the Plasmodium falciparum circumsporozoite protein gene in Tanzanian regions with different malaria endemicity Malaria J. (IF 3.0) Pub Date : 2024-05-08 Beatus M. Lyimo, Catherine Bakari, Zachary R. Popkin-Hall, David J. Giesbrecht, Misago D. Seth, Dativa Pereus, Zulfa I. Shabani, Ramadhan Moshi, Ruth Boniface, Celine I. Mandara, Rashid Madebe, Jonathan J. Juliano, Jeffrey A. Bailey, Deus S. Ishengoma
In 2021 and 2023, the World Health Organization approved RTS,S/AS01 and R21/Matrix M malaria vaccines, respectively, for routine immunization of children in African countries with moderate to high transmission. These vaccines are made of Plasmodium falciparum circumsporozoite protein (PfCSP), but polymorphisms in the gene raise concerns regarding strain-specific responses and the long-term efficacy
-
Molecular markers of artemisinin resistance during falciparum malaria elimination in Eastern Myanmar Malaria J. (IF 3.0) Pub Date : 2024-05-08 Aung Myint Thu, Aung Pyae Phyo, Chanapat Pateekhum, Jade D. Rae, Jordi Landier, Daniel M. Parker, Gilles Delmas, Wanitda Watthanaworawit, Alistair R. D. McLean, Ann Arya, Ann Reyes, Xue Li, Olivo Miotto, Kyaw Soe, Elizabeth A. Ashley, Arjen Dondorp, Nicholas J. White, Nicholas P. Day, Tim J. C. Anderson, Mallika Imwong, Francois Nosten, Frank Smithuis
Artemisinin resistance in Plasmodium falciparum threatens global malaria elimination efforts. To contain and then eliminate artemisinin resistance in Eastern Myanmar a network of community-based malaria posts was instituted and targeted mass drug administration (MDA) with dihydroartemisinin-piperaquine (three rounds at monthly intervals) was conducted. The prevalence of artemisinin resistance during
-
A qualitative look at bed net access and use in Burkina Faso, Mozambique, Nigeria, and Rwanda following piloted distributions of dual-active ingredient insecticide-treated nets Malaria J. (IF 3.0) Pub Date : 2024-05-07 Jenny Shannon, Moubassira Kagone, Baltazar Candrinho, Sylvanus Otikwu, Chantal Ingabire, Adama Gansane, Samy Pooda, Fofana Aboubacar, Fatou Ouattara, Binete Savaio, Celestino Joanguete, Lucio Sixpence, Hannah Koenker, Perpetua Uhomoibhi, Okefu Oyale Okoko, Onoja Ali, Dele Babarinde, Janet Ogundairo, Ayorinde Samuel Lemah, Aimable Mbituyumuremyi, Joseph H. Singirankabo, Nami Kawakyu, Federica Guglielmo
Universal coverage with insecticide-treated nets (ITNs) is important for malaria control and elimination. The emergence and intensification of insecticide resistance threatens progress made through the deployment of these interventions and has required the development of newer, more expensive ITN types. Understanding malaria prevention behaviour, including barriers and facilitators to net access and
-
Leveraging malaria vaccines and mRNA technology to tackle the global inequity in pharmaceutical research and production towards disease elimination Malaria J. (IF 3.0) Pub Date : 2024-05-06 Floriano Amimo
Malaria vaccine introduction in endemic countries is a game-changing milestone in the fight against the disease. This article examines the inequity in the global pharmaceutical research, development, manufacturing, and trade landscape. The role of inequity in hindering progress towards malaria elimination is explored. The analysis finds that transformational changes are required to create an equity-enabling
-
A simple, field-applicable method to increase the infectivity of wild isolates of Plasmodium falciparum to mosquito vectors Malaria J. (IF 3.0) Pub Date : 2024-05-06 Seydou Bienvenu Ouattara, Domonbabele F. D. S. Hien, Ekôbié T. Nao, Prisca S. L. Paré, Edwige Guissou, Anna Cohuet, Isabelle Morlais, Rakiswendé S. Yerbanga, Kounbobr R. Dabiré, Jean Bosco Ouédraogo, Karine Mouline, Thierry Lefèvre
The direct membrane feeding assay (DMFA), whereby gametocyte-infected blood is collected from human donors and from which mosquitoes feed through a membrane, is proving essential for assessing parameters influencing Plasmodium transmission potential in endemic countries. The success of DMFAs is closely tied to gametocyte density in the blood, with relatively high gametocytaemia ensuring optimal infection
-
A new long-read mitochondrial-genome protocol (PacBio HiFi) for haemosporidian parasites: a tool for population and biodiversity studies Malaria J. (IF 3.0) Pub Date : 2024-05-04 M. Andreína Pacheco, Axl S. Cepeda, Erica A. Miller, Scott Beckerman, Mitchell Oswald, Evan London, Nohra E. Mateus-Pinilla, Ananias A. Escalante
Studies on haemosporidian diversity, including origin of human malaria parasites, malaria's zoonotic dynamic, and regional biodiversity patterns, have used target gene approaches. However, current methods have a trade-off between scalability and data quality. Here, a long-read Next-Generation Sequencing protocol using PacBio HiFi is presented. The data processing is supported by a pipeline that uses
-
Statistical design and analysis of controlled human malaria infection trials Malaria J. (IF 3.0) Pub Date : 2024-05-03 Xiaowen Tian, Holly E. Janes, James G. Kublin
Malaria is a potentially life-threatening disease caused by Plasmodium protozoa transmitted by infected Anopheles mosquitoes. Controlled human malaria infection (CHMI) trials are used to assess the efficacy of interventions for malaria elimination. The operating characteristics of statistical methods for assessing the ability of interventions to protect individuals from malaria is uncertain in small
-
Repurposing of anti-malarial drugs for the treatment of tuberculosis: realistic strategy or fanciful dead end? Malaria J. (IF 3.0) Pub Date : 2024-05-03 Thomas Hanscheid, Claire Ruiz del Portal Luyten, Sabine M. Hermans, Martin P. Grobusch
Drug repurposing offers a strategic alternative to the development of novel compounds, leveraging the known safety and pharmacokinetic profiles of medications, such as linezolid and levofloxacin for tuberculosis (TB). Anti-malarial drugs, including quinolones and artemisinins, are already applied to other diseases and infections and could be promising for TB treatment. This review included studies
-
Predictors of accessing seasonal malaria chemoprevention medicines through non-door-to-door distribution in Nigeria Malaria J. (IF 3.0) Pub Date : 2024-05-03 Sikai Huang, Kevin Baker, Taiwo Ibinaiye, Olusola Oresanya, Chuks Nnaji, Sol Richardson
In Nigeria, seasonal malaria chemoprevention (SMC) is typically administered door-to-door to children under five by community medicine distributors during high transmission seasons. While door-to-door distribution (DDD) is exclusively employed in Nigeria as part of standard operating procedures of SMC programmes, some households access SMC through non-DDD channels, such as fixed-point distributions
-
Plasmodium falciparum alters the trophoblastic barrier and stroma villi organization of human placental villi explants Malaria J. (IF 3.0) Pub Date : 2024-05-01 Carolina López-Guzmán, Ana María García, Juan Diego Ramirez, Trinidad Torres Aliaga, Alejandro Fernández-Moya, Ulrike Kemmerling, Ana María Vásquez
The sequestration of Plasmodium falciparum infected erythrocytes in the placenta, and the resulting inflammatory response affects maternal and child health. Despite existing information, little is known about the direct impact of P. falciparum on the placental barrier formed by trophoblast and villous stroma. This study aimed to assess placental tissue damage caused by P. falciparum in human placental
-
Exploring the role of spending on malaria incidence in Uganda using the auto-regressive distributed lag approach Malaria J. (IF 3.0) Pub Date : 2024-04-30 Jemimah Katushabe, John Bosco Nnyanzi, Gertrude Sebunya Muwanga
Malaria has remained a persistent global health problem. Despite multiple government and donor initiatives to eradicate malaria and its detrimental effects on Uganda's health outcomes, the incidence of malaria is worrying as it appears higher than the average of 219 cases per 1000 for sub-Saharan Africa for the period 2017–2018. This study investigated the effect of public and private healthcare spending
-
Access to quality-assured artemisinin-based combination therapy and associated factors among clients of selected private drug outlets in Uganda Malaria J. (IF 3.0) Pub Date : 2024-04-30 Moses Ocan, Loyce Nakalembe, Caroline Otike, Tayebwa Mordecai, Joan Birungi, Sam Nsobya
Malaria treatment in sub-Saharan Africa is faced with challenges including unreliable supply of efficacious agents, substandard medicines coupled with high price of artemisinin-based combinations. This affects access to effective treatment increasing risk of malaria parasite resistance development and adverse drug events. This study investigated access to quality-assured artemisinin-based combination